Management of anxiety disorders: a review

mental illnesses worldwide. There were only two medications approved by the FDA to treat anxiety from 2008 to 2024, indicating that there are limitations with current pharmacodynamic therapies, and certainly harms, delayed onset of effectiveness, and a lack innovation considering the high prevalence and impact on society. This review article also incorporates data from clinical guidelines, drug development from the pharmaceutical industry, and active research articles related to herbal therapies. This review discusses the very promising anxiolytic potential of herbs, as augmented by their low-cost and excellent safety profiles. It also discussed history of use of conventional herbal medicine and the we discussed therapeutic roles of benzodiazepines, SSRIs, SNRIs, and pipeline experimental drugs. There is much to be learned however, including the need for models of integrative therapy practices, standardized clinical trials, and an investigation of mechanisms. This review summary highlights the increased interest in practical strategies for individuals to manage anxiety, especially in applicable clinical and community health contexts where accessibility based on evidence, acceptance and safety of interventions are important factors.